ascendis 2025 JPM Deck - Final version 01.12.25.pdf

1、J.P.Morgan Healthcare ConferenceSan FranciscoJanuary 2025Ascendis Pharma A/SFor investor communication only.Not for use in product promotion.Not for further distribution.This presentation contains forward-looking statements.All statements other than statements of historical facts contained in this p

2、resentation,such as statements regarding our products and prospective product candidates;revenue and growth expectations;PDUFA goal dates;clinical trial results;the expected timing of future clinical trial results,regulatory filings and feedback from regulatory authorities;the scope,progress,results

3、 and costs of developing our product candidates or any other future product candidates;timing and likelihood of success;patient enrollment;timing and expansion of commercial launches,pipelines,and investments;potential payments and royalties relating to investments and partnerships;plans and objecti

4、ves of management for future operations and commercialization and manufacturing activities;and future results of current and/or anticipated products and product candidates are forward-looking statements.These forward-looking statements are based on our current expectations and beliefs,as well as ass

5、umptions concerning future events.These statements involve known and unknown risks,uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements.These risks,uncertainties and other factors are more fully describe

6、d in our reports filed with or submitted to the Securities and Exchange Commission(“SEC”),including,without limitation,our prospectus supplement filed on September 20,2024 and our current and future reports filed with or submitted to the SEC,including our most recent Annual Report on Form 20-F filed